Scarica l'app Stockscreener
17.41
0.75%
0.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$17.28
Aprire:
$17.25
Volume 24 ore:
1.85M
Relative Volume:
1.19
Capitalizzazione di mercato:
$1.55B
Reddito:
$203.45M
Utile/perdita netta:
$-351.45M
Rapporto P/E:
-3.8264
EPS:
-4.55
Flusso di cassa netto:
$-369.41M
1 W Prestazione:
+4.38%
1M Prestazione:
+5.71%
6M Prestazione:
-24.96%
1 anno Prestazione:
+98.97%
Intervallo 1D:
$17.05
$17.74
Intervallo di 1 settimana:
$15.60
$17.74
Portata 52W:
$8.46
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Nome
Travere Therapeutics Inc
Settore
Industria
Telefono
888-969-7879
Indirizzo
3611 VALLEY CENTRE DR, SAN DIEGO
Confronta TVTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
17.41 | 1.54B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Reiterato | Citigroup | Buy |
| 2025-06-11 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-09 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-12-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-20 | Iniziato | Citigroup | Neutral |
| 2023-09-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Ripresa | Evercore ISI | Outperform |
| 2023-07-21 | Iniziato | JP Morgan | Overweight |
| 2023-06-07 | Ripresa | Piper Sandler | Neutral |
| 2023-05-22 | Iniziato | TD Cowen | Outperform |
| 2023-05-05 | Aggiornamento | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-21 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-12-14 | Iniziato | Stifel | Hold |
| 2022-12-05 | Iniziato | Wells Fargo | Overweight |
| 2022-09-21 | Iniziato | Bryan Garnier | Sell |
| 2022-07-14 | Ripresa | Canaccord Genuity | Buy |
| 2022-03-31 | Iniziato | Piper Sandler | Overweight |
| 2022-02-28 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-26 | Downgrade | Wedbush | Outperform → Neutral |
Mostra tutto
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Ichimoku Cloud Indicates Uncertainty Around Travere Therapeutics Inc. [Weekly Risk Report]Free Verified Swing Trading Watchlist - 선데이타임즈
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2025 Earnings Call Transcript - MSN
Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics (TVTX) Is Up 8.3% After Revenue Jump and Narrower Losses in Q2 – What's Changed - simplywall.st
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics price target raised to $34 from $32 at Citi - MSN
Healthcare Stocks Under the Spotlight: Eli Lilly & Co, Arrowhead Pharmaceuticals, and Travere Therapeutics - AInvest
Travere Therapeutics Reports Strong Q2 2025 Growth - MSN
Travere Therapeutics price target raised to $32 from $30 at Wedbush - Yahoo Finance
Travere Therapeutics Earnings Call Highlights FILSPARI Success - TipRanks
Scotiabank Raises Price Target for Travere Therapeutics (TVTX) t - GuruFocus
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Path To Profitability - simplywall.st
Travere Therapeutics price target raised to $31 from $30 at Scotiabank - TipRanks
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty - Investing.com
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty By Investing.com - Investing.com South Africa
Wedbush Lifts Price Target on Travere Therapeutics to $32 From $30, Keeps Outperform Rating - MarketScreener
TVTX: Wedbush Raises Price Target and Maintains Outperform Ratin - GuruFocus
Travere: Q2 Earnings Snapshot - Huron Daily Tribune
Travere signals accelerating FILSPARI growth and prepares for FSGS launch while advancing REMS modifications - MSN
Earnings call transcript: Travere Therapeutics Q2 2025 beats revenue forecasts - Investing.com Canada
Travere Therapeutics Reports Second Quarter 2025 Financial Results - BioSpace
Travere Therapeutics: Scaling the Rare Disease Ladder—Can FILSPARI Sustain Its Momentum? - AInvest
Contradictions Unveiled: Travere Therapeutics' 2025Q2 Earnings Call Highlights Regulatory Challenges and Market Dynamics - AInvest
Transcript : Travere Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Travere Therapeutics 2025 Q2 Earnings Strong Performance with 81.9% Net Loss Reduction - AInvest
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings - Yahoo Finance
Travere Therapeutics, Inc. SEC 10-Q Report - TradingView
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Travere Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Travere Therapeutics shares rise as Q2 results top expectations By Investing.com - Investing.com Australia
Travere Therapeutics shares rise as Q2 results top expectations - Investing.com India
Travere Therapeutics Inc Reports Q2 2025 Earnings: EPS Loss of $0.14 Beats Estimates, Revenue Surpasses Expectations at $114.4 Million - GuruFocus
Travere Therapeutics earnings beat by $0.16, revenue topped estimates - Investing.com Canada
Is Travere Therapeutics (NASDAQ:TVTX) Using Too Much Debt? - 富途牛牛
Travere Therapeutics to Participate at Upcoming Investor ConferencesAugust 5, 2025 - BioSpace
Earnings Preview: Travere Therapeutics - 富途牛牛
RBC to announce third quarter results on August 27, 2025 - The Globe and Mail
Trend Dashboard Flags Travere Therapeutics Inc. As Potential Swing TradeExpert Verified Stock Trade Ideas Backed by Data - metal.it
What are the technical indicators suggesting about Travere Therapeutics Inc.Achieve triple-digit returns with smart investing - Jammu Links News
Should I hold or sell Travere Therapeutics Inc. stock in 2025Grow your portfolio with growth-oriented stocks - Jammu Links News
How does Travere Therapeutics Inc. generate profit in a changing economyFree Investment Community - Jammu Links News
When is Travere Therapeutics Inc. stock expected to show significant growthDouble or triple returns - Jammu Links News
How many analysts rate Travere Therapeutics Inc. as a “Buy”Explosive capital gains - Jammu Links News
Is Travere Therapeutics Inc. a good long term investmentUnlock market-leading stock analysis - Jammu Links News
How does Travere Therapeutics Inc. compare to its industry peersExceptional trading performance - Jammu Links News
How strong is Travere Therapeutics Inc. company’s balance sheetPost Market Guidance With High Returns - jammulinksnews.com
What is Travere Therapeutics Inc. company’s growth strategyTop Growth Data Feed From AI Tools - jammulinksnews.com
Travere Therapeutics to Report Second Quarter 2025 Financial Results - BioSpace
Why Travere Therapeutics Inc. stock attracts strong analyst attentionAccurate Buy Point for Momentum Stocks Detected - beatles.ru
Travere Therapeutics Inc Azioni (TVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):